TDMS Study 05031-01 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
MERCURIC CHLORIDE
NTP Experiment-Test: 05031-01 Report: PEIRPT03
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 16:24:44
Facility: International Research and Development Corp.
Chemical CAS #: 7487-94-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 4 11 8
Dead 5 4 10
Gavage Death 1
Survivors
Terminal Sacrifice 41 35 31
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50)
Erosion 1 (2%)
Inflammation, Chronic Active 1 (2%)
Gallbladder (38) (41) (35)
Cyst 1 (3%) 1 (3%)
Inflammation, Chronic 4 (10%)
Intestine Large (49) (50) (50)
Anus, Inflammation, Acute 1 (2%)
Intestine Large, Cecum (45) (49) (42)
Parasite Metazoan 1 (2%)
Serosa, Fibrosis 1 (2%)
Intestine Large, Colon (49) (50) (48)
Serosa, Fibrosis 1 (2%) 1 (2%)
Intestine Large, Rectum (44) (46) (49)
Submucosa, Cyst 1 (2%)
Intestine Small, Duodenum (45) (47) (43)
Serosa, Fibrosis 1 (2%)
Intestine Small, Ileum (47) (44) (44)
Peyer's Patch, Hyperplasia, Lymphoid 2 (4%)
Serosa, Fibrosis 1 (2%)
Intestine Small, Jejunum (48) (48) (41)
Hyperplasia, Lymphoid 2 (4%)
Serosa, Fibrosis 1 (2%)
Liver (50) (50) (50)
Angiectasis 2 (4%) 1 (2%)
Clear Cell Focus 1 (2%) 1 (2%)
Congestion 2 (4%)
Eosinophilic Focus 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic 13 (26%) 21 (42%) 18 (36%)
Inflammation, Chronic Active 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Necrosis 3 (6%) 3 (6%)
Pigmentation 1 (2%) 1 (2%)
Thrombosis 1 (2%)
Hepatocyte, Atrophy 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (2%)
Serosa, Fibrosis 1 (2%) 1 (2%)
Mesentery (6) (1) (3)
Inflammation, Chronic 1 (17%)
Inflammation, Chronic Active 1 (33%)
Fat, Necrosis 3 (50%)
Pancreas (50) (50) (47)
Atrophy 3 (6%) 3 (6%) 1 (2%)
Eosinophilic Focus 1 (2%) 2 (4%)
Fibrosis 2 (4%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic 1 (2%) 3 (6%)
Duct, Cyst 5 (10%) 3 (6%)
Salivary Glands (49) (48) (50)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%)
Stomach, Forestomach (48) (50) (48)
Hyperkeratosis 1 (2%) 2 (4%)
Hyperplasia, Squamous 2 (4%) 3 (6%)
Inflammation, Chronic 1 (2%)
Serosa, Fibrosis 1 (2%)
Stomach, Glandular (48) (50) (46)
Erosion 1 (2%) 3 (6%) 2 (4%)
Ulcer, Multiple 1 (2%)
Serosa, Fibrosis 1 (2%)
Tongue (1)
Hyperplasia, Squamous 1 (100%)
Tooth (1) (1)
Developmental Malformation 1 (100%)
Peridontal Tissue, Inflammation,
Granulomatous 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Degeneration 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Mineralization 2 (4%) 1 (2%)
Coronary Artery, Inflammation, Chronic Active 1 (2%)
Epicardium, Fibrosis 1 (2%)
Epicardium, Inflammation, Chronic Active 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Valve, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (49) (50)
Congestion 1 (2%)
Cyst 1 (2%)
Degeneration 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 1 (2%)
Hypertrophy, Focal 1 (2%) 1 (2%) 2 (4%)
Mineralization 1 (2%)
Subcapsular, Hyperplasia 48 (98%) 48 (98%) 50 (100%)
Adrenal Gland, Medulla (49) (48) (49)
Hyperplasia, Focal 1 (2%) 2 (4%) 1 (2%)
Islets, Pancreatic (49) (50) (46)
Hyperplasia 1 (2%) 1 (2%)
Pituitary Gland (49) (47) (45)
Cyst 1 (2%)
Hyperplasia, Focal 4 (8%) 4 (9%) 3 (7%)
Thyroid Gland (50) (49) (49)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 2 (4%)
Follicle, Cyst 2 (4%) 3 (6%) 3 (6%)
Follicular Cell, Hyperplasia 1 (2%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (3) (3)
Mediastinum, Inflammation, Chronic Active 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (49) (50)
Abscess 1 (2%)
Angiectasis 2 (4%) 1 (2%) 1 (2%)
Cyst 16 (33%) 18 (37%) 15 (30%)
Cyst, Multiple 6 (12%) 6 (12%) 4 (8%)
Hyperplasia, Tubular 1 (2%)
Pigmentation 1 (2%)
Interstitium, Hyperplasia 1 (2%)
Periovarian Tissue, Inflammation, Chronic
Active 1 (2%)
Uterus (50) (50) (49)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Angiectasis 2 (4%)
Fibrosis 1 (2%)
Hydrometra 1 (2%)
Inflammation, Acute 1 (2%) 1 (2%)
Thrombosis 1 (2%)
Cervix, Hyperplasia, Squamous 3 (6%)
Cervix, Inflammation, Acute 1 (2%) 6 (12%) 1 (2%)
Cervix, Inflammation, Chronic 1 (2%)
Endometrium, Hyperplasia, Cystic 43 (86%) 44 (88%) 34 (69%)
Serosa, Fibrosis 1 (2%)
Vagina (4) (8)
Hyperkeratosis 1 (25%)
Inflammation, Acute 4 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Atrophy 1 (2%)
Myelofibrosis 40 (80%) 36 (72%) 30 (60%)
Pigmentation 1 (2%)
Myeloid Cell, Hyperplasia 7 (14%)
Lymph Node (44) (44) (48)
Iliac, Hyperplasia, Lymphoid 1 (2%)
Iliac, Hyperplasia, Plasma Cell 1 (2%)
Iliac, Pigmentation 1 (2%)
Inguinal, Hyperplasia, Lymphoid 1 (2%)
Inguinal, Hyperplasia, Plasma Cell 1 (2%)
Mandibular, Cyst, Multiple 1 (2%)
Mandibular, Hyperplasia, Lymphoid 2 (5%) 1 (2%)
Mediastinal, Fibrosis 1 (2%)
Mediastinal, Hyperplasia, Lymphoid 3 (7%)
Mediastinal, Hyperplasia, Plasma Cell 1 (2%)
Mediastinal, Pigmentation 1 (2%)
Mediastinal, Thrombosis 1 (2%)
Mesenteric, Angiectasis 1 (2%)
Mesenteric, Cyst 1 (2%)
Mesenteric, Hyperplasia, Lymphoid 1 (2%)
Pancreatic, Hyperplasia, Lymphoid 1 (2%)
Renal, Hyperplasia, Lymphoid 1 (2%)
Spleen (49) (50) (48)
Hematopoietic Cell Proliferation 1 (2%) 2 (4%) 4 (8%)
Hyperplasia, Lymphoid 8 (16%) 3 (6%) 5 (10%)
Thrombosis 1 (2%)
Capsule, Fibrosis 1 (2%) 2 (4%)
Thymus (41) (39) (43)
Atrophy 1 (2%) 4 (10%) 4 (9%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Congestion 1 (2%)
Cyst 1 (2%) 2 (5%) 2 (5%)
Ectopic Parathyroid Gland 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 3 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (47) (46) (46)
Inflammation, Chronic 1 (2%)
Acinus, Hyperplasia 1 (2%) 3 (7%)
Duct, Cyst 1 (2%) 1 (2%)
Duct, Hyperplasia 1 (2%)
Skin (50) (50) (50)
Acanthosis 3 (6%) 10 (20%)
Cyst 1 (2%) 1 (2%)
Exudate 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Hydrocephalus 1 (2%)
Mineralization 21 (42%) 23 (46%) 16 (32%)
Meninges, Fibrosis 1 (2%)
Meninges, Infiltration Cellular, Lymphocyte 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Congestion 1 (2%) 1 (2%) 2 (4%)
Fibrosis, Multifocal 1 (2%)
Fungus 1 (2%)
Hemorrhage 3 (6%) 2 (4%) 3 (6%)
Inflammation, Granulomatous 1 (2%)
Leukocytosis 1 (2%)
Thrombosis 1 (2%)
Alveolar Epithelium, Hyperplasia, Focal 2 (4%)
Alveolus, Infiltration Cellular, Histiocyte 2 (4%) 2 (4%) 4 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5MG/KG 10MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Artery, Media, Hypertrophy 4 (8%) 2 (4%) 3 (6%)
Bronchus, Inflammation, Acute 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 3 (6%) 6 (12%) 4 (8%)
Pleura, Fibrosis 2 (4%)
Pleura, Inflammation, Chronic Active 1 (2%)
Nose (50) (50) (50)
Angiectasis 1 (2%)
Exudate 3 (6%) 10 (20%) 17 (34%)
Inflammation, Acute 2 (4%) 3 (6%) 9 (18%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 5 (10%)
Olfactory Epithelium, Metaplasia 1 (2%) 20 (40%) 46 (92%)
Trachea (50) (49) (50)
Inflammation, Chronic 1 (2%)
Metaplasia, Squamous 1 (2%)
Peritracheal Tissue, Inflammation, Chronic
Active 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50)
Autolysis 3 (6%)
Cyst 1 (2%)
Hydronephrosis 1 (2%)
Nephropathy 21 (43%) 43 (86%) 42 (84%)
Glomerulus, Thrombosis 1 (2%)
Pelvis, Mineralization 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (2%) 2 (4%)
Renal Tubule, Necrosis, Acute 1 (2%)
Urinary Bladder (48) (48) (47)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%) 2 (4%)
Metaplasia, Squamous 2 (4%)
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Dead 8 10 8
Moribund 6 4 11
Survivors
Terminal Sacrifice 35 36 31
Dead 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49) (48) (49)
Ulcer, Chronic 1 (2%)
Periesophageal Tissue, Foreign Body 1 (2%)
Periesophageal Tissue, Inflammation, Acute 1 (2%)
Intestine Large, Rectum (47) (47) (49)
Prolapse 1 (2%)
Serosa, Inflammation, Acute 1 (2%) 1 (2%)
Intestine Small, Jejunum (48) (43) (45)
Peyer's Patch, Hyperplasia, Lymphoid 2 (4%)
Liver (50) (50) (50)
Abscess, Chronic 1 (2%)
Basophilic Focus 2 (4%)
Clear Cell Focus 1 (2%)
Congestion 4 (8%)
Cyst 1 (2%) 1 (2%) 1 (2%)
Eosinophilic Focus 1 (2%)
Hematopoietic Cell Proliferation Granulocytic 1 (2%)
Infarct 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 3 (6%) 3 (6%)
Inflammation, Chronic Active 1 (2%)
Leukocytosis 2 (4%)
Necrosis 3 (6%) 1 (2%)
Vein, Inflammation, Chronic Active 1 (2%)
Mesentery (3) (2)
Inflammation, Acute 1 (33%) 1 (50%)
Artery, Inflammation, Chronic Active 1 (33%)
Fat, Necrosis 1 (33%)
Pancreas (50) (46) (49)
Atrophy 1 (2%) 6 (13%) 3 (6%)
Basophilic Focus 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 1 (2%)
Artery, Inflammation, Chronic Active 2 (4%)
Duct, Cyst 2 (4%) 2 (4%)
Pharynx (2)
Cyst 1 (50%)
Inflammation, Acute 2 (100%)
Salivary Glands (50) (48) (49)
Atrophy 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Stomach, Forestomach (50) (48) (50)
Hyperplasia, Squamous 3 (6%)
Stomach, Glandular (49) (47) (49)
Erosion 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Inflammation, Chronic 1 (2%)
Tooth (3) (2) (3)
Developmental Malformation 2 (67%) 1 (50%)
Peridontal Tissue, Inflammation, Acute 1 (33%) 1 (33%)
Peridontal Tissue, Inflammation, Chronic
Active 1 (33%)
Peridontal Tissue, Inflammation,
Granulomatous 2 (67%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
Abscess 1 (2%)
Degeneration 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Mineralization 7 (14%) 1 (2%)
Thrombosis 1 (2%)
Coronary Artery, Inflammation, Chronic Active 1 (2%)
Epicardium, Fibrosis 1 (2%)
Epicardium, Inflammation, Acute 1 (2%)
Valve, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (49)
Congestion 1 (2%)
Cyst 1 (2%)
Hyperplasia 2 (4%)
Hypertrophy, Focal 3 (6%) 4 (8%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Subcapsular, Hyperplasia 41 (82%) 38 (76%) 36 (73%)
Islets, Pancreatic (49) (47) (48)
Hyperplasia 3 (6%) 2 (4%)
Parathyroid Gland (34) (34) (32)
Cyst 2 (6%)
Pituitary Gland (48) (47) (47)
Cyst 1 (2%) 1 (2%)
Hyperplasia 1 (2%)
Thyroid Gland (49) (47) (49)
Inflammation, Chronic 1 (2%) 1 (2%)
Follicle, Crystals 1 (2%)
Follicle, Cyst 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Fat, Pelvic, Inflammation, Chronic 1 (100%)
Mediastinum, Angiectasis 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50)
Dilatation 2 (4%)
Granuloma Sperm 1 (2%)
Hypospermia 1 (2%)
Inflammation, Chronic 1 (2%)
Penis (4) (2) (6)
Inflammation, Acute 2 (50%)
Inflammation, Chronic Active 1 (50%)
Preputial Gland (12) (17) (3)
Abscess 3 (25%) 4 (24%) 1 (33%)
Inflammation, Acute 2 (17%)
Inflammation, Chronic 1 (8%) 3 (18%) 1 (33%)
Inflammation, Chronic Active 3 (25%) 1 (33%)
Duct, Cyst 7 (58%) 14 (82%) 3 (100%)
Prostate (46) (49) (46)
Inflammation, Acute 2 (4%) 4 (8%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 1 (2%) 2 (4%)
Seminal Vesicle (9) (3) (3)
Dilatation 2 (22%) 1 (33%)
Testes (50) (50) (50)
Degeneration 4 (8%) 2 (4%) 7 (14%)
Artery, Inflammation, Chronic 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Seminiferous Tubule, Dilatation, Focal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Infiltration Cellular, Mast Cell 1 (2%)
Myeloid Cell, Hyperplasia 4 (8%) 2 (4%) 4 (8%)
Lymph Node (44) (48) (43)
Axillary, Hyperplasia, Plasma Cell 1 (2%)
Iliac, Hyperplasia, Lymphoid 1 (2%)
Iliac, Hyperplasia, Plasma Cell 2 (4%)
Inguinal, Hyperplasia, Lymphoid 2 (5%) 2 (5%)
Inguinal, Hyperplasia, Plasma Cell 1 (2%) 2 (4%)
Inguinal, Pigmentation 1 (2%) 3 (7%)
Mandibular, Infiltration Cellular, Histiocyte 1 (2%)
Mediastinal, Hyperplasia, Lymphoid 2 (5%) 2 (5%)
Mediastinal, Inflammation, Acute 1 (2%)
Mesenteric, Hyperplasia, Lymphoid 2 (4%) 2 (5%)
Pancreatic, Hematopoietic Cell Proliferation 1 (2%)
Spleen (50) (49) (49)
Hematopoietic Cell Proliferation 3 (6%) 1 (2%) 4 (8%)
Hematopoietic Cell Proliferation Granulocytic 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 3 (6%)
Thymus (26) (34) (27)
Atrophy 1 (4%) 3 (11%)
Cyst 4 (15%) 6 (18%) 2 (7%)
Ectopic Parathyroid Gland 1 (4%)
Hyperplasia, Lymphoid 1 (3%)
Necrosis 5 (19%) 1 (3%) 5 (19%)
Epithelial Cell, Hyperplasia 2 (7%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50)
Abscess 1 (2%)
Acanthosis 3 (6%)
Fibrosis 1 (2%)
Hyperplasia, Focal, Squamous 1 (2%)
Inflammation, Acute 3 (6%) 2 (4%)
Inflammation, Chronic 3 (6%) 1 (2%) 1 (2%)
Inflammation, Chronic Active 2 (4%)
Ulcer 1 (2%) 1 (2%)
Abdominal, Abscess 1 (2%)
Face, Cyst 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Inguinal, Ulcer 1 (2%)
Prepuce, Abscess 1 (2%)
Prepuce, Ulcer 1 (2%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Inflammation,
Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (2)
Abdominal, Inflammation, Acute 1 (50%)
Abdominal, Mineralization 1 (50%)
Thoracic, Inflammation, Acute 1 (50%)
Thoracic, Metaplasia 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50)
Congestion 1 (2%)
Hemorrhage 1 (2%)
Mineralization 21 (42%) 29 (59%) 26 (52%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Congestion 3 (6%) 3 (6%) 2 (4%)
Hemorrhage 4 (8%) 1 (2%)
Inflammation, Acute 1 (2%) 3 (6%)
Leukocytosis 2 (4%) 1 (2%)
Mineralization 1 (2%)
Thrombosis 1 (2%)
Alveolar Epithelium, Hyperplasia, Focal 3 (6%) 1 (2%) 2 (4%)
Alveolus, Infiltration Cellular, Histiocyte 2 (4%) 3 (6%)
Artery, Thrombosis 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (2%)
Pleura, Fibrosis 1 (2%)
Pleura, Inflammation, Acute 1 (2%)
Vein, Thrombosis 3 (6%)
Nose (50) (50) (50)
Angiectasis 1 (2%)
Exudate 3 (6%) 9 (18%) 20 (40%)
Inflammation, Acute 1 (2%) 3 (6%) 14 (28%)
Inflammation, Chronic 1 (2%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Nasolacrimal Duct, Cyst 1 (2%)
Olfactory Epithelium, Metaplasia 3 (6%) 8 (16%) 41 (82%)
Trachea (50) (50) (50)
Inflammation, Acute 1 (2%)
Peritracheal Tissue, Foreign Body 1 (2%)
Peritracheal Tissue, Inflammation, Acute 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Autolysis 1 (2%)
Cyst 4 (8%) 2 (4%) 9 (18%)
Hydronephrosis 1 (2%) 1 (2%)
Infarct 1 (2%)
Inflammation, Acute 1 (2%) 2 (4%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 1 (2%)
Nephropathy 40 (80%) 45 (90%) 44 (90%)
Artery, Inflammation, Chronic Active 2 (4%)
Glomerulus, Inflammation, Acute 1 (2%)
Pelvis, Inflammation, Acute 1 (2%) 1 (2%) 1 (2%)
Pelvis, Transitional Epithelium, Hyperplasia 1 (2%)
Renal Tubule, Hyperplasia 2 (4%)
Renal Tubule, Hyperplasia, Focal 1 (2%)
Ureter (1)
Inflammation, Chronic 1 (100%)
Urethra (1) (1) (2)
Dilatation 1 (100%) 1 (50%)
Inflammation, Acute 1 (100%)
Inflammation, Chronic Active 1 (50%)
Urinary Bladder (45) (48) (46)
Calculus Gross Observation 1 (2%) 2 (4%)
Calculus Micro Observation Only 2 (4%) 1 (2%)
Dilatation 1 (2%)
Inflammation, Acute 2 (4%) 3 (6%) 1 (2%)
Inflammation, Chronic Active 1 (2%) 2 (4%)
Mineralization 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 05031-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 16:24:44
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5MG/KG 10MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------